Oral anticoagulation: Preparing for change

Journal of the American Medical Directors Association

Volumn 5, Issue 5 SUPPL., 2004, Pages 2-10

  Nutescu, Edith A ^a   Spyropoulos, Alex C ^b   Cranmer, Kerry W ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Lovelace Health Systems   (United States)

^c 1601 Lowell Blvd   (United States)

Author keywords

Anticoagulants; Deep vein thrombosis; Prevention; Stroke; Treatment; Venous thromboembolism; Warfarin; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; DESULFATOHIRUDIN; ENOXAPARIN; HEPARIN; HIRULOG; LEPIRUDIN; PLACEBO; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG TOLERABILITY; GERIATRICS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PREVALENCE; STROKE; THROMBOEMBOLISM; TITRIMETRY; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

EID: 23744472130     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70033-X     Document Type: Conference Paper

References (35)

1. Buntinx F, Devroey D, Van Casteren V. The incidence of stroke and transient ischaemic attacks is falling: a report from the Belgian sentinel stations. Br J Gen Pract. 2002;52:813-7.
2. Heart Disease and Stroke Statistics-2004 Update. American Heart Association. In; 2004:1-48.
3. Wenger NK, Scheldt S, Weber MA. Anticoagulation at elderly age: the challenge to do better. Am J Geriatr Cardiol. 2003;12:151-2.
4. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469-73.
5. Goldhaber SZ. Deep-vein thrombosis: advancing awareness to protect patient lives. American Public Health Association. 2003:1-12.
6. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Jr., Wheeler HB. Prevention of venous thromboembolism. Chest. 2001;119:1325-1755.
7. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
8. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-6.
9. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-26.
10. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marier JR. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med. 2003;138:831-8.
11. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:645-945.
12. Current Guidelines for Practice-oral anticoagulation for older adults. Chest. 1998;114:4395-7695.
13. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119: 194S-206S.
14. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:1765-1935.
15. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med. 1996;334:682-7.
16. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-81.
17. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med. 1997;337:657-62.
18. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001;345:165-9.
19. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-9.
20. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-62.
21. Smith NL, Psaty BM, Furberg CD, White R, Lima JA, Newman AB, Manolio TA. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med. 1999;159:1574-8.
22. McCormick D, Gurwitz JH, Goldberg RJ, Becker R, Tate JP, Elwell A, Radford MJ. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001; 161:2458-63.
23. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157:978-84.
24. Bungard TJ, Ackman ML, Ho G, Tsuyuki RT. Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacothempy. 2000;20:1060-5.
25. Top 10 dangerous drug interactions in the elderly. Assisted Living Nursing Report. 2002;4:3.
26. USP: Top 50 Drug Products Associated with Medication Errors. In; 2004.
27. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmaeother. 2004;38:99-109.
28. Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 2003;59:35-43.
29. Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislen K, Eager G, Gustafsson D. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2003;31:294-305.
30. Sarich TC, Teng R, Peters GR, Wollbratt M, Homolka R, Svensson M, Eriksson UG. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet. 2003;42: 485-92.
31. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res. 1999;94:187-97.
32. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-8.
33. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003; 146:431-8.
34. Huisman M. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran for acute deep vein thrombosis with or without pulmonary embolism. In: Congress of the International Society on Thrombosis and Haemostasis. Birgingham, UK; 2003.
35. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713-21.